AstraZeneca’s Imfinzi gets FDA orphan drug status for small cell lung cancer

AstraZeneca’s Imfinzi gets FDA orphan drug status for small cell lung cancer

Submitted by admin on July 16, 2019 - 10:59am
Source: 
Pharmaceutical Business Review
News Tags: 
AstraZeneca
Imfinzi
FDA
small cell lung cancer
orphan drugs
Headline: 
AstraZeneca’s Imfinzi gets FDA orphan drug status for small cell lung cancer
snippet: 

AstraZeneca’s oncology immunotherapy Imfinzi (durvalumab) has been granted orphan drug designation (ODD) for the treatment of small cell lung cancer (SCLC).